(Q30788622)

26 June 2017

Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial (English)

1 reference

26 June 2017

0 references

1 reference

11

Jean-Louis Vincent

1 reference

26 June 2017

4

Gordon R Bernard

1 reference

26 June 2017

Jan Bakker

6

1 reference

ORCID Public Data File 2021

author name string

Jean-François Dhainaut

1

1 reference

26 June 2017

Pierre-François Laterre

2

1 reference

26 June 2017

Jonathan M Janes

3

1 reference

26 June 2017

Antonio Artigas

5

1 reference

26 June 2017

Hanno Riess

7

1 reference

26 June 2017

Bruce R Basson

8

1 reference

26 June 2017

Julien Charpentier

9

1 reference

26 June 2017

Barbara G Utterback

10

1 reference

26 June 2017

Recombinant Human Activated Protein C Worldwide Evaluation in Sepsis (PROWESS) Study Group

12

1 reference

26 June 2017

24 April 2003

1 reference

26 June 2017

Intensive Care Medicine

1 reference

26 June 2017

29

1 reference

26 June 2017

6

1 reference

26 June 2017

894-903

1 reference

https://scigraph.springernature.com/pub.10.1007/s00134-003-1731-1

26 June 2017

0 references

cites work

American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference

1 reference

https://api.crossref.org/works/10.1007%2FS00134-003-1731-1

Epidemiology of sepsis: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-003-1731-1

Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-003-1731-1

Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-003-1731-1

The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-003-1731-1

Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-003-1731-1

Sepsis and evolution of the innate immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-003-1731-1

New therapeutic targets revealed through investigations of innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-003-1731-1

Vascular bed-specific hemostasis: role of endothelium in sepsis pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-003-1731-1

The endothelium in sepsis: source of and a target for inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-003-1731-1

Gene expression profile of antithrombotic protein c defines new mechanisms modulating inflammation and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-003-1731-1

The anticoagulant and anti-inflammatory roles of the protein C anticoagulant pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-003-1731-1

Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-003-1731-1

Recombinant human activated protein C: a system modulator of vascular function for treatment of severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-003-1731-1

Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-003-1731-1

Efficacy and safety of recombinant human activated protein C for severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-003-1731-1

Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-003-1731-1

Assessing the use of activated protein C in the treatment of severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-003-1731-1

Risks and benefits of activated protein C treatment for severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-003-1731-1

APACHE II: a severity of disease classification system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-003-1731-1

Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-003-1731-1

Prognosis in acute organ-system failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-003-1731-1

Pharmacokinetic-pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-003-1731-1

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-003-1731-1

Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-003-1731-1

The revised CONSORT statement for reporting randomized trials: explanation and elaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-003-1731-1

Debate: Subgroup analyses in clinical trials: fun to look at - but don't believe them!

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00134-003-1731-1

Activated protein C concentrate for the treatment of meningococcal endotoxin shock in rabbits

21 January 2018

1 reference

12 December 2020

Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production

1 reference

12 December 2020

Multiple systems organ failure: epidemiology and prognosis

1 reference

12 December 2020

Activated protein C prevents multiple organ injury following extensive hepatectomy in cirrhotic rats

1 reference

12 December 2020

Mechanism of protein C-dependent clot lysis: role of plasminogen activator inhibitor

1 reference

12 December 2020

Statistical methods in cancer research. Volume I - The analysis of case-control studies.

1 reference

12 December 2020

Activated Protein C for Severe Sepsis

1 reference

12 December 2020

Microvascular responses to sepsis: clinical significance

1 reference

12 December 2020

Alterations in coagulation and fibrinolysis during sepsis.

1 reference

12 December 2020

American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis

1 reference

12 December 2020

The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine

1 reference

12 December 2020

An enhanced fibrinolysis prevents the development of multiple organ failure in disseminated intravascular coagulation in spite of much activation of blood coagulation

1 reference

12 December 2020

Activation of the extrinsic coagulation pathway in patients with severe sepsis and septic shock

1 reference

12 December 2020

Mechanism of Inhibition of Activated Protein C by Protein C Inhibitor 1

1 reference

12 December 2020

10.1007/S00134-003-1731-1

Identifiers

DOI

0 references

1 reference